纳米医学药物递送增强通透性和保留效应在肿瘤学中的挑战和关键考虑因素。
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.
机构信息
Alliance for Nanotechnology in Cancer, National Cancer Institute, Bethesda, MD 20892, USA.
出版信息
Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.
Abstract
Enhanced permeability of the tumor vasculature allows macromolecules to enter the tumor interstitial space, whereas the suppressed lymphatic filtration allows them to stay there. This phenomenon, enhanced permeability and retention (EPR), has been the basis of nanotechnology platforms to deliver drugs to tumors. However, progress in developing effective drugs using this approach has been hampered by heterogeneity of EPR effect in different tumors and limited experimental data from patients on effectiveness of this mechanism as related to enhanced drug accumulation. This report summarizes the workshop discussions on key issues of the EPR effect and major gaps that need to be addressed to effectively advance nanoparticle-based drug delivery.
摘要
肿瘤血管的通透性增强使大分子能够进入肿瘤间质空间，而抑制的淋巴过滤则使它们能够留在那里。这种现象，即增强的通透性和保留（EPR），一直是纳米技术平台将药物递送到肿瘤的基础。然而，利用这种方法开发有效药物的进展受到不同肿瘤中 EPR 效应的异质性以及患者关于该机制与增强药物积累相关的有效性的有限实验数据的阻碍。本报告总结了关于 EPR 效应的关键问题和需要解决的主要差距的研讨会讨论，以有效推进基于纳米粒子的药物输送。
相似文献
1
Challenges and key considerations of the enhanced permeability and retention effect for nanomedicine drug delivery in oncology.纳米医学药物递送增强通透性和保留效应在肿瘤学中的挑战和关键考虑因素。
Cancer Res. 2013 Apr 15;73(8):2412-7. doi: 10.1158/0008-5472.CAN-12-4561. Epub 2013 Feb 19.
2
Human solid tumors and clinical relevance of the enhanced permeation and retention effect: a 'golden gate' for nanomedicine in preclinical studies?人体实体瘤与增强渗透和滞留效应的临床相关性：纳米医学在临床前研究中的“黄金之门”？
Nanomedicine (Lond). 2023 Jan;18(2):169-190. doi: 10.2217/nnm-2022-0257. Epub 2023 Apr 12.
3
Parameters Affecting the Enhanced Permeability and Retention Effect: The Need for Patient Selection.影响增强型通透性和保留效应的参数：患者选择的必要性。
J Pharm Sci. 2017 Nov;106(11):3179-3187. doi: 10.1016/j.xphs.2017.06.019. Epub 2017 Jun 29.
4
Tumor targeting via EPR: Strategies to enhance patient responses.通过 EPR 进行肿瘤靶向：增强患者反应的策略。
Adv Drug Deliv Rev. 2018 May;130:17-38. doi: 10.1016/j.addr.2018.07.007. Epub 2018 Jul 19.
5
Nanodrug Delivery: Is the Enhanced Permeability and Retention Effect Sufficient for Curing Cancer?纳米药物递送：增强的渗透与滞留效应足以治愈癌症吗？
Bioconjug Chem. 2016 Oct 19;27(10):2225-2238. doi: 10.1021/acs.bioconjchem.6b00437. Epub 2016 Sep 2.
6
The EPR effect and beyond: Strategies to improve tumor targeting and cancer nanomedicine treatment efficacy.EPR 效应及超越：提高肿瘤靶向性和癌症纳米医学治疗效果的策略。
Theranostics. 2020 Jun 25;10(17):7921-7924. doi: 10.7150/thno.49577. eCollection 2020.
7
Design considerations for nanotherapeutics in oncology.肿瘤学中纳米治疗药物的设计考量
Nanomedicine. 2015 Nov;11(8):1893-907. doi: 10.1016/j.nano.2015.07.015. Epub 2015 Aug 15.
8
Perspectives for Improving the Tumor Targeting of Nanomedicine via the EPR Effect in Clinical Tumors.通过临床肿瘤中的 EPR 效应提高纳米医学肿瘤靶向性的展望。
Int J Mol Sci. 2023 Jun 13;24(12):10082. doi: 10.3390/ijms241210082.
9
Toward a full understanding of the EPR effect in primary and metastatic tumors as well as issues related to its heterogeneity.为了充分了解原发性和转移性肿瘤中的 EPR 效应以及与其异质性相关的问题。
Adv Drug Deliv Rev. 2015 Aug 30;91:3-6. doi: 10.1016/j.addr.2015.01.002. Epub 2015 Jan 9.
10
To exploit the tumor microenvironment: Since the EPR effect fails in the clinic, what is the future of nanomedicine?利用肿瘤微环境：既然 EPR 效应在临床上失败了，那么纳米医学的未来在哪里？
J Control Release. 2016 Dec 28;244(Pt A):108-121. doi: 10.1016/j.jconrel.2016.11.015. Epub 2016 Nov 18.
引用本文的文献
1
Structural and functional properties of neodymium-doped hydroxyapatite nanoparticles for biomedical applications.用于生物医学应用的掺钕羟基磷灰石纳米颗粒的结构和功能特性
Biotechnol Rep (Amst). 2025 Aug 15;48:e00916. doi: 10.1016/j.btre.2025.e00916. eCollection 2025 Dec.
2
The Role of miRNA167 in Skin Improvement: Insight from Extracellular Vesicles Derived from Rock Samphire ().miRNA167在皮肤改善中的作用：来自岩生海蓬子细胞外囊泡的见解（）
Biomolecules. 2025 Aug 12;15(8):1157. doi: 10.3390/biom15081157.
3
Targeting oncofetal fibronectin and neuropilin-1 in solid tumors with PL2 peptide.用PL2肽靶向实体瘤中的癌胚纤连蛋白和神经纤毛蛋白-1。
Sci Rep. 2025 Aug 11;15(1):29369. doi: 10.1038/s41598-025-11299-x.
4
Application of Nanotechnology in TACE Treatment of Liver Cancer.纳米技术在肝癌经动脉化疗栓塞治疗中的应用
Int J Nanomedicine. 2025 Aug 4;20:9621-9639. doi: 10.2147/IJN.S527518. eCollection 2025.
5
Role of borneol as enhancer in drug formulation: A review.冰片在药物制剂中作为增溶剂的作用：综述。
Chin Herb Med. 2024 May 17;17(3):473-483. doi: 10.1016/j.chmed.2024.04.003. eCollection 2025 Jul.
6
Analyzing Molecular Determinants of Nanodrugs' Cytotoxic Effects.分析纳米药物细胞毒性作用的分子决定因素。
Int J Mol Sci. 2025 Jul 11;26(14):6687. doi: 10.3390/ijms26146687.
7
Advances in Doxorubicin Chemotherapy: Emerging Polymeric Nanocarriers for Drug Loading and Delivery.阿霉素化疗的进展：用于药物负载和递送的新型聚合物纳米载体
Cancers (Basel). 2025 Jul 10;17(14):2303. doi: 10.3390/cancers17142303.
8
Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.癌症相关成纤维细胞在癌症耐药性和癌症进展中的作用：综述
Cell Death Discov. 2025 Jul 24;11(1):341. doi: 10.1038/s41420-025-02566-x.
9
Development of Immune-Regulatory Pseudo-Protein-Coated Iron Oxide Nanoparticles for Enhanced Treatment of Triple-Negative Breast Tumor.用于增强三阴性乳腺癌治疗的免疫调节假蛋白包被氧化铁纳米颗粒的研发
Nanomaterials (Basel). 2025 Jun 30;15(13):1006. doi: 10.3390/nano15131006.
10
Surface-Anchored Ticagrelor Gelatin Nanoparticles-Platelets System for Enhanced Anti-PD-L1 Therapy Response and Boosted Chemotherapeutic Efficacy of Nanomedicines.用于增强抗PD-L1治疗反应和提高纳米药物化疗疗效的表面锚定替格瑞洛明胶纳米颗粒-血小板系统
Exploration (Beijing). 2025 Mar 6;5(3):20240084. doi: 10.1002/EXP.20240084. eCollection 2025 Jun.
本文引用的文献
1
Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers.将肿瘤微环境正常化以治疗癌症：从实验室到临床再到生物标志物。
J Clin Oncol. 2013 Jun 10;31(17):2205-18. doi: 10.1200/JCO.2012.46.3653. Epub 2013 May 13.
2
The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo.高分子药物传递的 EPR 效应：提高肿瘤摄取率、降低全身毒性、并在体内进行独特的肿瘤成像。
Adv Drug Deliv Rev. 2013 Jan;65(1):71-9. doi: 10.1016/j.addr.2012.10.002. Epub 2012 Oct 23.
3
Liposome imaging agents in personalized medicine.个性化医学中的脂质体成像剂。
Adv Drug Deliv Rev. 2012 Oct;64(13):1417-35. doi: 10.1016/j.addr.2012.09.003. Epub 2012 Sep 12.
4
Comparison of mAbs targeting epithelial cell adhesion molecule for the detection of prostate cancer lymph node metastases with multimodal contrast agents: quantitative small-animal PET/CT and NIRF.针对上皮细胞黏附分子的单克隆抗体用于检测前列腺癌淋巴结转移的比较：多模态对比剂的定量小动物 PET/CT 和 NIRF。
J Nucl Med. 2012 Sep;53(9):1427-37. doi: 10.2967/jnumed.112.106302. Epub 2012 Aug 7.
5
Macromolecular therapeutics in cancer treatment: the EPR effect and beyond.癌症治疗中的高分子治疗学：EPR 效应及超越
J Control Release. 2012 Dec 10;164(2):138-44. doi: 10.1016/j.jconrel.2012.04.038. Epub 2012 May 1.
6
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile.一种具有差异化药代动力学特征的 PSMA 靶向多西他赛纳米颗粒的临床前开发和临床转化。
Sci Transl Med. 2012 Apr 4;4(128):128ra39. doi: 10.1126/scitranslmed.3003651.
7
Interpatient pharmacokinetic and pharmacodynamic variability of carrier-mediated anticancer agents.载体介导的抗癌药物的患者间药代动力学和药效学变异性。
Clin Pharmacol Ther. 2012 May;91(5):802-12. doi: 10.1038/clpt.2012.12.
8
Targeted polymeric therapeutic nanoparticles: design, development and clinical translation.靶向聚合物治疗纳米粒：设计、开发与临床转化。
Chem Soc Rev. 2012 Apr 7;41(7):2971-3010. doi: 10.1039/c2cs15344k. Epub 2012 Mar 5.
9
Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention effect in solid tumors.一氧化碳由血红素加氧酶-1 生成，介导实体瘤中的增强通透性和保留效应。
Cancer Sci. 2012 Mar;103(3):535-41. doi: 10.1111/j.1349-7006.2011.02178.x. Epub 2012 Jan 16.
10
Translation of near-infrared fluorescence imaging technologies: emerging clinical applications.近红外荧光成像技术的翻译：新兴的临床应用。
Annu Rev Med. 2012;63:217-31. doi: 10.1146/annurev-med-070910-083323. Epub 2011 Oct 27.
Zotero 插件